Jennison Associates
REGN icon

Jennison Associates’s Regeneron Pharmaceuticals REGN Stock Holding History

Jennison Associates’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-17,700
Closed -$6.86M – 660
2017
Q1 		$6.86M Hold
17,700
– – 0.01% 501
2016
Q4 		$6.5M Buy
+17,700
New +$6.73M 0.01% 500
2016
Q2 		– Sell
-18,600
Closed -$6.7M – 656
2016
Q1 		$6.7M Buy
+18,600
New +$7.66M 0.01% 478

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Jennison Associates's REGN Position: Q2 2026 in Review

Jennison Associates sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 115,199 shares — an estimated $89M sold.

Jennison Associates first reported a position in REGN in Q2 2015 and held it in 23 quarters. The position peaked at $1.09B in Q4 2015. 1,340 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Jennison Associates reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Jennison Associates sold 115,199 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $89M.
  • Jennison Associates first reported a position in Regeneron Pharmaceuticals in Q2 2015 and held it in 23 quarters.
  • Jennison Associates's Regeneron Pharmaceuticals position peaked at $1.09B in Q4 2015.
  • 1,340 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Jennison Associates's 13F filing for Q2 2026, filed 3 Aug 2026.